Full Author : ['Gerstein, Hertzel C', 'Colhoun, Helen M', 'Dagenais, Gilles R', 'Diaz, Rafael', 'Lakshmanan, Mark', 'Pais, Prem', 'Probstfield, Jeffrey', 'Botros, Fady T', 'Riddle, Matthew C', 'Ryden, Lars', 'Xavier, Denis', 'Atisso, Charles Messan', 'Dyal, Leanne', 'Hall, Stephanie', 'Rao-Melacini, Purnima', 'Wong, Gloria', 'Avezum, Alvaro', 'Basile, Jan', 'Chung, Namsik', 'Conget, Ignacio', 'Cushman, William C', 'Franek, Edward', 'Hancu, Nicolae', 'Hanefeld, Markolf', 'Holt, Shaun', 'Jansky, Petr', 'Keltai, Matyas', 'Lanas, Fernando', 'Leiter, Lawrence A', 'Lopez-Jaramillo, Patricio', 'Cardona Munoz, Ernesto German', 'Pirags, Valdis', 'Pogosova, Nana', 'Raubenheimer, Peter J', 'Shaw, Jonathan E', 'Sheu, Wayne H-H', 'Temelkova-Kurktschiev, Theodora']
Journal Title : Lancet (London, England)
Chapter : Section3
Journal Year : 2019
Cited by : Not Available
BACKGROUND: Two glucagon-like peptide-1 (GLP-1) receptor agonists reduced renal outcomes in people with type 2 diabetes at risk for cardiovascular disease. We assessed the long-term effect of the GLP-1 receptor agonist dulaglutide on renal outcomes in an .....
